The EMA has lost a high court battle to cancel its £500-million long-term office lease in London.
News
Abbott and Novo Nordisk strike diabetes digital solution deal
Abbott and Novo Nordisk have entered into a partnership to provide integrated digital solutions to people with diabetes, using insulin.
New cancer drug payment system could speed up treatment
A new report suggests that paying for cancer drugs based on how well they work in practice could help patients get new treatments faster.
FDA thumbs up for Esperoct in haemophilia A
Novo Nordisk has received US approval for haemophilia A drug Esperoct.
Gov unveils launch of NHSX for digital, data and tech
The government has announced plans to create a new joint organisation for digital, data and technology, to be called NHSX.
Last chance to get your entry in for the 2019 Clinical Researcher of the Year – The Americas competition
This established, challenging, and free-to-enter competition will close for entry on the 25th February – don’t miss out on this great personal development opportunity.
FDA Priority Review for Roche’s entrectinib in cancer treatment
Roche has announced that the FDA has granted Priority Review for entrectinib as a treatment for NTRK fusion-positive, locally advanced or metastatic solid tumours, and to treat metastatic ROS1-positive non-small-cell lung cancer.
Keytruda falls short in late-stage liver cancer trial
MSD’s anti-PD-1 therapy Keytruda did not meet its co-primary endpoints in the Phase III KEYNOTE-240 trial involving patients with liver cancer.
First subject dosed in endocrine disorders trial
Sosei has announced that the first subject has been dosed in a UK-based Phase I study of HTL0030310.
Pfizer’s biosimilar Zirabev wins EU approval
Pfizer has announced European approval of its Avastin biosimilar Zirabev.
Intercept’s fatty liver drug one step closer to approval
Intercept Pharmaceuticals has announced that its treatment in patients with a progressive fatty liver disease showed an improvement in scarring on the organ.
New sepsis test can diagnose in less than three minutes
New sepsis takes just two and a half minutes to diagnose the disease, meaning it could help save up to 14,000 lives a year.
Genome editing successful in correcting muscular dystrophy in mice
Researchers at Duke University have shown that CRISPR genome editing technology can safely and stably correct Duchenne muscular dystrophy in mice.
First patient dosed in Gyroscope Therapeutics’ AMD study
Gyroscope Therapeutics has announced that the first patient has been dosed in its Phase I/II FOCUS study for dry age-related macular degeneration (AMD).
Report finds NICE’s routine appraisals need reform
A report by MAP BioPharma has found that NICE’s appraisal of rare disease medicines does not deliver equal access for patients.
